Merck KGaA (MKKGY) Lags Q4 Earnings Estimates

分组1 - Merck KGaA reported quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.47 per share, and down from $0.54 per share a year ago, representing an earnings surprise of -40.43% [1] - The company posted revenues of $6.11 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.69%, and up from $5.78 billion year-over-year [2] - Merck KGaA shares have added about 0.4% since the beginning of the year, matching the S&P 500's gain of 0.4% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Merck KGaA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $5.87 billion, and for the current fiscal year, it is $1.93 on revenues of $24.39 billion [7] 分组3 - The Medical - Drugs industry, to which Merck KGaA belongs, is currently in the top 37% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]